Continue Methimazole on Day of Appendectomy in Euthyroid Patients
Yes, continue methimazole on the day of appendectomy in euthyroid patients on stable antithyroid therapy. The available evidence addresses thyroid surgery specifically, but the principles extend to non-thyroid surgery with important distinctions.
Key Distinction: Thyroid vs. Non-Thyroid Surgery
The guideline evidence specifically addresses thyroidectomy, where Recommendation 27 states: "Antithyroid drugs should be stopped at the time of thyroidectomy for GD" 1. However, this recommendation applies only to thyroid surgery where the thyroid gland itself is being removed, making continued thyroid suppression unnecessary and potentially complicating postoperative management.
For Non-Thyroid Surgery (Like Appendectomy)
The situation is fundamentally different for appendectomy or other non-thyroid surgeries:
- Continue methimazole to maintain the euthyroid state you've already achieved
- The patient is already biochemically stable and euthyroid
- Stopping methimazole risks precipitating hyperthyroidism perioperatively
- There is no therapeutic reason to discontinue when the thyroid gland remains in place
Recent evidence supports that cardiovascular stability matters more than absolute biochemical euthyroidism 2. A 2024 review found that thyroidectomy can be safely performed even in the hyperthyroid state by experienced teams without precipitating thyroid storm 2. If surgery is safe in hyperthyroid patients, it is certainly safe in already-euthyroid patients continuing their maintenance therapy.
Clinical Reasoning
Why continue methimazole:
- Your patient has achieved stable euthyroid status on current therapy
- Methimazole has a relatively short half-life (4-6 hours); missing doses risks losing thyroid control
- The stress of surgery and anesthesia can potentially worsen thyroid hormone excess
- No evidence suggests methimazole interferes with appendectomy or general anesthesia
The only scenario to stop would be thyroidectomy itself 1, where continuation serves no purpose post-removal of thyroid tissue.
Perioperative Management Algorithm
For your euthyroid patient on stable methimazole undergoing appendectomy:
- Continue methimazole at current dose on the morning of surgery with sip of water
- Resume regular dosing postoperatively once oral intake tolerated
- Monitor cardiovascular status (heart rate, blood pressure) as you would routinely
- No need for additional preoperative iodine or beta-blockade if already euthyroid and cardiovascularly stable
Important Caveats
Watch for drug interactions 3:
- Methimazole may enhance warfarin effects if patient is anticoagulated
- Beta-blocker requirements may change if thyroid status shifts
- These are monitoring issues, not contraindications to continuing therapy
The FDA label 3 emphasizes close surveillance for adverse effects (agranulocytosis, hepatotoxicity) but does not contraindicate perioperative use. These are chronic concerns, not acute surgical contraindications.
If the patient were hyperthyroid (not your scenario), guidelines recommend achieving euthyroid state before elective surgery 1. However, recent literature 2, 4, 5 suggests that with appropriate cardiovascular optimization (beta-blockade), even urgent surgery can proceed safely in hyperthyroid patients when necessary.
Bottom Line
Continue the methimazole. The guideline recommendation to stop antithyroid drugs applies specifically to thyroidectomy where the target organ is removed 1. For appendectomy in a stable, euthyroid patient, continuing methimazole maintains the therapeutic goal you've already achieved and prevents perioperative thyroid decompensation.